Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 1

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Authors Esteban Jódar-Gimeno

Published 15 April 2007 Volume 2007:2(1) Pages 163—174

Esteban Jódar-Gimeno

Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain

Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.

Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.

Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.

Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.

Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.

Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)

Download Article [PDF] 

Readers of this article also read:

Mechanisms underlying probucol-induced hERG-channel deficiency

Shi YQ, Yan CC, Zhang X, Yan M, Liu LR, Geng HZ, Lv L, Li BX

Drug Design, Development and Therapy 2015, 9:3695-3704

Published Date: 20 July 2015

Postural stability and quality of life after guided and self-training among older adults residing in an institutional setting

Tuunainen E, Rasku J, Jäntti P, Moisio-Vilenius P, Mäkinen E, Toppila E, Pyykkö I

Clinical Interventions in Aging 2013, 8:1237-1246

Published Date: 16 September 2013

Update on the use of dutasteride in the management of benign prostatic hypertrophy

Joe Miller, Thomas H Tarter

Clinical Interventions in Aging 2007, 2:99-104

Published Date: 15 April 2007

Walker use, but not falls, is associated with lower physical functioning and health of residents in an assisted-living environment

Daniel A Andersen, Bernard A Roos, Damian C Stanziano, Natasha M Gonzalez, Joseph F Signorile

Clinical Interventions in Aging 2007, 2:123-137

Published Date: 15 April 2007

Rivastigmine in the treatment of Alzheimer's disease: an update

Maria Luisa Onor, Marianna Trevisiol, Eugenio Aguglia

Clinical Interventions in Aging 2007, 2:17-32

Published Date: 15 April 2007

Immunological outcomes of exercise in older adults

David S Senchina, Marian L Kohut

Clinical Interventions in Aging 2007, 2:3-16

Published Date: 15 April 2007

Role of 5 alpha-reductase inhibitors in the management of prostate cancer

Steven J Hudak, Javier Hernandez, Ian M Thompson

Clinical Interventions in Aging 2006, 1:425-431

Published Date: 15 January 2007